Combined HP <sup>13</sup>C Pyruvate and <sup>13</sup>C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts.

Combined HP ¹³C Pyruvate and ¹³C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts.

Farah, Chantale; Neveu, Marie-Aline; Yelek, Caner; Bouzin, Caroline; Gallez, Bernard; Baurain, Jean-François; Mignion, Lionel; Jordan, Bénédicte F.

Affiliation

Farah C; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, UCLouvain, B-1200 Brussels, Belgium.
Neveu MA; Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, KU Leuven, B-3000 Leuven, Belgium.
Yelek C; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, UCLouvain, B-1200 Brussels, Belgium.
Bouzin C; IREC Imaging Platform, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, UCLouvain, B-1200 Brussels, Belgium.
Gallez B; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, UCLouvain, B-1200 Brussels, Belgium.
Baurain JF; Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium.
Mignion L; Molecular Imaging and Radiation Oncology (MIRO) Group, Institute de Recherche Expérimentale et Clinique (IREC), B-1200 Brussels, Belgium.
Jordan BF; Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, UCLouvain, B-1200 Brussels, Belgium.

Biomedicines ; 10(3)2022 Mar 19.

Article in En | MEDLINE | ID: mdl-35327519